Cargando…

Intranasal Oxytocin as an adjunct treatment in patients with major depression with and without comorbid borderline personality disorder

INTRODUCTION: The mechanisms leading to Oxytocin’s differential effects among patients with borderline personality disorder have thus far been elusive. OBJECTIVES: This study was aimed to explore the differential effect of OT administration among depressive patients with or without comorbid borderli...

Descripción completa

Detalles Bibliográficos
Autor principal: Maoz, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595993/
http://dx.doi.org/10.1192/j.eurpsy.2023.513
_version_ 1785124999297761280
author Maoz, H.
author_facet Maoz, H.
author_sort Maoz, H.
collection PubMed
description INTRODUCTION: The mechanisms leading to Oxytocin’s differential effects among patients with borderline personality disorder have thus far been elusive. OBJECTIVES: This study was aimed to explore the differential effect of OT administration among depressive patients with or without comorbid borderline personality disorder, and to explore the mediating role of attachment in these differential patterns. METHODS: Patients treated with psychotherapy in an inpatient settings (N=58) were randomized and double-blindly allocated to receive oxytocin or placebo for a period of four weeks. The effect of OT on therapy process and outcome was examined among patients with (n=35) and without (n=23) borderline personality disorder. Moderated mediational models were estimated to explore whether attachment differentially affected the association between oxytocin and treatment outcomes. RESULTS: patients without BPD showed significantly larger improvements following OT administration (B=-8.32, p=.001) as compared to placebo in OQ-45. On the other hand, patients with BPD showed no significant improvement following OT (B=0.61, p=.76). The same pattern was observed in the HSCL, where patients without BPD demonstrated significantly larger improvements following OT administration (B=-0.29 ,p=.0009) as compared to placebo, while patients with BPD demonstrated no significant improvement (B=-0.04 ,p=.55). Moderated mediational models indicated no significant moderated indirect effect, however, a significant trend of indirect effect only in the BPD group was observed, whereby the no-BPD group showed a stronger direct effect (β=-0.19, t=-1.30, p=.20), whereas the BPD group showed a stronger indirect effect (β=-0.72, SE=0.45, CI= -1,71, -0.00). CONCLUSIONS: Patients with depression and comorbid BPD benefit less from OT administration as compared depressive patients without such comorbidity. It is possible that the involvement of the attachment system may be associated with the attenuation of OT’s effect. DISCLOSURE OF INTEREST: None Declared
format Online
Article
Text
id pubmed-10595993
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-105959932023-10-25 Intranasal Oxytocin as an adjunct treatment in patients with major depression with and without comorbid borderline personality disorder Maoz, H. Eur Psychiatry Abstract INTRODUCTION: The mechanisms leading to Oxytocin’s differential effects among patients with borderline personality disorder have thus far been elusive. OBJECTIVES: This study was aimed to explore the differential effect of OT administration among depressive patients with or without comorbid borderline personality disorder, and to explore the mediating role of attachment in these differential patterns. METHODS: Patients treated with psychotherapy in an inpatient settings (N=58) were randomized and double-blindly allocated to receive oxytocin or placebo for a period of four weeks. The effect of OT on therapy process and outcome was examined among patients with (n=35) and without (n=23) borderline personality disorder. Moderated mediational models were estimated to explore whether attachment differentially affected the association between oxytocin and treatment outcomes. RESULTS: patients without BPD showed significantly larger improvements following OT administration (B=-8.32, p=.001) as compared to placebo in OQ-45. On the other hand, patients with BPD showed no significant improvement following OT (B=0.61, p=.76). The same pattern was observed in the HSCL, where patients without BPD demonstrated significantly larger improvements following OT administration (B=-0.29 ,p=.0009) as compared to placebo, while patients with BPD demonstrated no significant improvement (B=-0.04 ,p=.55). Moderated mediational models indicated no significant moderated indirect effect, however, a significant trend of indirect effect only in the BPD group was observed, whereby the no-BPD group showed a stronger direct effect (β=-0.19, t=-1.30, p=.20), whereas the BPD group showed a stronger indirect effect (β=-0.72, SE=0.45, CI= -1,71, -0.00). CONCLUSIONS: Patients with depression and comorbid BPD benefit less from OT administration as compared depressive patients without such comorbidity. It is possible that the involvement of the attachment system may be associated with the attenuation of OT’s effect. DISCLOSURE OF INTEREST: None Declared Cambridge University Press 2023-07-19 /pmc/articles/PMC10595993/ http://dx.doi.org/10.1192/j.eurpsy.2023.513 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Maoz, H.
Intranasal Oxytocin as an adjunct treatment in patients with major depression with and without comorbid borderline personality disorder
title Intranasal Oxytocin as an adjunct treatment in patients with major depression with and without comorbid borderline personality disorder
title_full Intranasal Oxytocin as an adjunct treatment in patients with major depression with and without comorbid borderline personality disorder
title_fullStr Intranasal Oxytocin as an adjunct treatment in patients with major depression with and without comorbid borderline personality disorder
title_full_unstemmed Intranasal Oxytocin as an adjunct treatment in patients with major depression with and without comorbid borderline personality disorder
title_short Intranasal Oxytocin as an adjunct treatment in patients with major depression with and without comorbid borderline personality disorder
title_sort intranasal oxytocin as an adjunct treatment in patients with major depression with and without comorbid borderline personality disorder
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595993/
http://dx.doi.org/10.1192/j.eurpsy.2023.513
work_keys_str_mv AT maozh intranasaloxytocinasanadjuncttreatmentinpatientswithmajordepressionwithandwithoutcomorbidborderlinepersonalitydisorder